Remission & chronicity
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: Clinical > Mechanistic > Correlative.
ALDH2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| DEHYDRATED ALCOHOL | ? unclear | Mechanistic | DGIdb | |
| ACETALDEHYDE | ? unclear | Mechanistic | DGIdb | |
| DISULFIRAM | ↓ inhibits | Mechanistic | 3400.0 nM (IC50) | DGIdb |
| NALTREXONE | ? unclear | Mechanistic | DGIdb | |
| PRUNETIN | ↓ inhibits | Mechanistic | 450.0 nM (Ki) | DGIdb |
| HEROIN | ? unclear | Mechanistic | DGIdb | |
| DOCETAXEL ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| CISPLATIN | ? unclear | Mechanistic | DGIdb | |
| NITROGLYCERIN | ? unclear | Mechanistic | DGIdb | |
| MIRIVADELGAT | ? unclear | Mechanistic | DGIdb | |
| DAIDZIN | ↓ inhibits | Mechanistic | 40.0 nM (IC50) | ChEMBL |
| CHEMBL112007 | ↓ inhibits | Mechanistic | 9.0 nM (IC50) | ChEMBL |
| CHEMBL113617 | ↓ inhibits | Mechanistic | 270.0 nM (IC50) | ChEMBL |
| CHEMBL115314 | ↓ inhibits | Mechanistic | 260.0 nM (IC50) | ChEMBL |
| CHEMBL112165 | ↓ inhibits | Mechanistic | 800.0 nM (IC50) | ChEMBL |
| CHEMBL113640 | ↓ inhibits | Mechanistic | 9.0 nM (IC50) | ChEMBL |
| CHEMBL115092 | ↓ inhibits | Mechanistic | 40.0 nM (IC50) | ChEMBL |
| CHEMBL132065 | ↓ inhibits | Mechanistic | 100.0 nM (IC50) | ChEMBL |
| CHEMBL113123 | ↓ inhibits | Mechanistic | 3.0 nM (IC50) | ChEMBL |
| CHEMBL112437 | ↓ inhibits | Mechanistic | 300.0 nM (IC50) | ChEMBL |
| CHEMBL112696 | ↓ inhibits | Mechanistic | 4.0 nM (IC50) | ChEMBL |
| DAIDZEIN | ↓ inhibits | Mechanistic | 9000.0 nM (IC50) | ChEMBL |
| CHEMBL134275 | ↓ inhibits | Mechanistic | 400.0 nM (IC50) | ChEMBL |
| CHEMBL113855 | ↓ inhibits | Mechanistic | 7200.0 nM (IC50) | ChEMBL |
| CHEMBL262662 | ↓ inhibits | Mechanistic | 130.0 nM (IC50) | ChEMBL |
| CHEMBL113586 | ↓ inhibits | Mechanistic | 100.0 nM (IC50) | ChEMBL |
| CHEMBL112286 | ↓ inhibits | Mechanistic | 2500.0 nM (IC50) | ChEMBL |
| CHEMBL419936 | ↓ inhibits | Mechanistic | 1200.0 nM (IC50) | ChEMBL |
| CHEMBL115161 | ↓ inhibits | Mechanistic | 1700.0 nM (IC50) | ChEMBL |
| CHEMBL109868 | ↓ inhibits | Mechanistic | 250.0 nM (IC50) | ChEMBL |
| CHEMBL110038 | ↓ inhibits | Mechanistic | 3500.0 nM (IC50) | ChEMBL |
| CHEMBL114083 | ↓ inhibits | Mechanistic | 40.0 nM (IC50) | ChEMBL |
| 4'-HYDROXYCHALCONE | ↓ inhibits | Mechanistic | 7000.0 nM (IC50) | ChEMBL |
| CHEMBL324628 | ↓ inhibits | Mechanistic | 1000.0 nM (IC50) | ChEMBL |
| CHEMBL112070 | ↓ inhibits | Mechanistic | 280.0 nM (IC50) | ChEMBL |
| CHEMBL113113 | ↓ inhibits | Mechanistic | 70.0 nM (IC50) | ChEMBL |
| CHEMBL113058 | ↓ inhibits | Mechanistic | 120.0 nM (IC50) | ChEMBL |
| CHEMBL326803 | ↓ inhibits | Mechanistic | 130.0 nM (IC50) | ChEMBL |
| CHEMBL112865 | ↓ inhibits | Mechanistic | 240.0 nM (IC50) | ChEMBL |
| CHEMBL111984 | ↓ inhibits | Mechanistic | 150.0 nM (IC50) | ChEMBL |
Showing top 40 of 170 agents ranked by evidence tier.
DRD2
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| LOXAPINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| MINAPRINE | ↑ activates | Mechanistic | DGIdb | |
| SULPIRIDE | ↓ inhibits | Mechanistic | DGIdb | |
| HALOPERIDOL DECANOATE | ↓ inhibits | Mechanistic | DGIdb | |
| ZIPRASIDONE MESYLATE | ↓ inhibits | Mechanistic | DGIdb | |
| METHYLDOPA ANHYDROUS | ? unclear | Mechanistic | DGIdb | |
| BENPERIDOL | ↓ inhibits | Mechanistic | DGIdb | |
| FLUSPIRILENE | ↓ inhibits | Mechanistic | DGIdb | |
| VERALIPRIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CAFFEINE | ? unclear | Mechanistic | DGIdb | |
| SUMANIROLE | ↑ activates | Mechanistic | 9.0 nM (Ki) | DGIdb |
| ZIPRASIDONE | ↓ inhibits | Mechanistic | DGIdb | |
| METOCLOPRAMIDE HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| LUMATEPERONE | ↓ inhibits | Mechanistic | DGIdb | |
| FLUPENTHIXOL | ↓ inhibits | Mechanistic | DGIdb | |
| PROCHLORPERAZINE | ↓ inhibits | Mechanistic | DGIdb | |
| PERAZINE | ? unclear | Mechanistic | DGIdb | |
| FLUPHENAZINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ROPINIROLE | ↑ activates | Mechanistic | DGIdb | |
| RACLOPRIDE | ↓ inhibits | Mechanistic | DGIdb | |
| PROMAZINE | ↓ inhibits | Mechanistic | DGIdb | |
| [3H]PD128907 | ↑ activates | Mechanistic | DGIdb | |
| MORPHINE SULFATE | ? unclear | Mechanistic | DGIdb | |
| ALIZAPRIDE | ↓ inhibits | Mechanistic | DGIdb | |
| PHENYLTOLOXAMINE | ? unclear | Mechanistic | DGIdb | |
| LOXAPINE | ↓ inhibits | Mechanistic | DGIdb | |
| CABERGOLINE | ↑ activates | Mechanistic | DGIdb | |
| BREXPIPRAZOLE | ↑ activates | Mechanistic | DGIdb | |
| PALIPERIDONE | ↓ inhibits | Mechanistic | DGIdb | |
| APLINDORE FUMARATE | ↑ activates | Mechanistic | DGIdb | |
| APOMORPHINE | ↑ activates | Mechanistic | DGIdb | |
| CARIPRAZINE | ↑ activates | Mechanistic | DGIdb | |
| MOLINDONE | ? unclear | Mechanistic | DGIdb | |
| TIAPRIDE | ↓ inhibits | Mechanistic | DGIdb | |
| ZOTEPINE | ↓ inhibits | Mechanistic | DGIdb | |
| DOPAMINE | ↑ activates | Mechanistic | DGIdb | |
| XP21279 | ? unclear | Mechanistic | DGIdb | |
| PROMAZINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| VILAZODONE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| TRIFLUPROMAZINE | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 372 agents ranked by evidence tier.
GABRA1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| PICROTOXIN | ? unclear | Mechanistic | DGIdb | |
| THIAMYLAL SODIUM | ~ modulates | Mechanistic | DGIdb | |
| GANAXOLONE | ~ modulates | Mechanistic | DGIdb | |
| BUTOBARBITAL | ? unclear | Mechanistic | DGIdb | |
| CHLORDIAZEPOXIDE | ~ modulates | Mechanistic | DGIdb | |
| CLOBAZAM | ~ modulates | Mechanistic | DGIdb | |
| CLORAZEPATE | ? unclear | Mechanistic | DGIdb | |
| TPA023 | ~ modulates | Mechanistic | DGIdb | |
| ZK-93423 | ? unclear | Mechanistic | DGIdb | |
| FLUMAZENIL | ~ modulates | Mechanistic | 3.3 nM (Ki) | DGIdb |
| AMOBARBITAL | ? unclear | Mechanistic | DGIdb | |
| PAGOCLONE | ~ modulates | Mechanistic | DGIdb | |
| OXAZEPAM | ~ modulates | Mechanistic | DGIdb | |
| TETRAHYDRODEOXYCORTICOSTERONE | ~ modulates | Mechanistic | DGIdb | |
| METHOHEXITAL | ? unclear | Mechanistic | DGIdb | |
| CLONAZEPAM | ~ modulates | Mechanistic | DGIdb | |
| [3H]GABAZINE | ↓ inhibits | Mechanistic | DGIdb | |
| FLURAZEPAM | ? unclear | Mechanistic | DGIdb | |
| METHARBITAL | ~ modulates | Mechanistic | DGIdb | |
| LORAZEPAM | ~ modulates | Mechanistic | DGIdb | |
| RO4938581 | ~ modulates | Mechanistic | DGIdb | |
| SECOBARBITAL | ? unclear | Mechanistic | DGIdb | |
| BUTABARBITAL SODIUM | ~ modulates | Mechanistic | DGIdb | |
| MIDAZOLAM HYDROCHLORIDE | ~ modulates | Mechanistic | DGIdb | |
| SANDARACOPIMARIC ACID | ? unclear | Mechanistic | DGIdb | |
| QUAZEPAM | ~ modulates | Mechanistic | DGIdb | |
| PHENOBARBITAL | ? unclear | Mechanistic | DGIdb | |
| PRIMIDONE | ~ modulates | Mechanistic | DGIdb | |
| ISOGUVACINE | ↑ activates | Mechanistic | DGIdb | |
| ZOLPIDEM TARTRATE | ~ modulates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL2170369 | ? unclear | Mechanistic | DGIdb | |
| ESTAZOLAM | ~ modulates | Mechanistic | DGIdb | |
| TOPIRAMATE | ~ modulates | Mechanistic | DGIdb | |
| ETHCHLORVYNOL | ~ modulates | Mechanistic | DGIdb | |
| CLORAZEPATE DIPOTASSIUM | ~ modulates | Mechanistic | DGIdb | |
| ZALEPLON | ~ modulates | Mechanistic | DGIdb | |
| FLUNITRAZEPAM | ~ modulates | Mechanistic | 4.5 nM (Kd) | DGIdb |
| BUTABARBITAL | ? unclear | Mechanistic | DGIdb | |
| THIAMYLAL | ? unclear | Mechanistic | DGIdb | |
| BUTALBITAL | ~ modulates | Mechanistic | DGIdb |
Showing top 40 of 302 agents ranked by evidence tier.
GRIN1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| AV-101 | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 8 [PMID: 17562362} | ↓ inhibits | Mechanistic | DGIdb | |
| KETAMINE HYDROCHLORIDE | ~ modulates | Mechanistic | DGIdb | |
| SERINE, D- | ↑ activates | Mechanistic | DGIdb | |
| 5,7-DICHLOROKYNURENIC ACID | ↓ inhibits | Mechanistic | DGIdb | |
| PHILANTHOTOXIN 343 | ? unclear | Mechanistic | DGIdb | |
| FELBAMATE | ↓ inhibits | Mechanistic | DGIdb | |
| AMANTADINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| (+)-HA966 | ↑ activates | Mechanistic | DGIdb | |
| NEBOGLAMINE | ~ modulates | Mechanistic | DGIdb | |
| AZD8108 | ↓ inhibits | Mechanistic | DGIdb | |
| CNS-5161 | ? unclear | Mechanistic | DGIdb | |
| D-SERINE | ? unclear | Mechanistic | DGIdb | |
| GLYCINE | ↑ activates | Mechanistic | DGIdb | |
| [3H]CGP39653 | ↓ inhibits | Mechanistic | DGIdb | |
| EVT-101 | ↓ inhibits | Mechanistic | DGIdb | |
| DEXANABINOL | ? unclear | Mechanistic | DGIdb | |
| ORPHENADRINE | ? unclear | Mechanistic | DGIdb | |
| TRAXOPRODIL | ↓ inhibits | Mechanistic | DGIdb | |
| ESKETAMINE HYDROCHLORIDE | ~ modulates | Mechanistic | DGIdb | |
| ESKETAMINE | ~ modulates | Mechanistic | DGIdb | |
| MEMANTINE HYDROCHLORIDE | ~ modulates | Mechanistic | DGIdb | |
| DELUCEMINE | ↓ inhibits | Mechanistic | DGIdb | |
| [3H]L689560 | ↓ inhibits | Mechanistic | DGIdb | |
| RALFINAMIDE | ↓ inhibits | Mechanistic | DGIdb | |
| APIMOSTINEL | ↑ activates | Mechanistic | DGIdb | |
| CYCLOSERINE | ? unclear | Mechanistic | DGIdb | |
| [3H]CGP61594 | ↓ inhibits | Mechanistic | DGIdb | |
| GW468816 | ↓ inhibits | Mechanistic | DGIdb | |
| [3H]CPP | ↓ inhibits | Mechanistic | DGIdb | |
| LATREPIRDINE | ? unclear | Mechanistic | DGIdb | |
| NBQX | ? unclear | Mechanistic | DGIdb | |
| [3H]CGS19755 | ↓ inhibits | Mechanistic | DGIdb | |
| ORPHENADRINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| [3H]D-ASPARTIC ACID | ↑ activates | Mechanistic | DGIdb | |
| ORPHENADRINE CITRATE | ↓ inhibits | Mechanistic | DGIdb | |
| (RS)-(TETRAZOL-5-YL)GLYCINE | ↑ activates | Mechanistic | DGIdb | |
| DIZOCILPINE | ? unclear | Mechanistic | DGIdb | |
| RADIPRODIL | ↓ inhibits | Mechanistic | DGIdb | |
| PERZINFOTEL | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 188 agents ranked by evidence tier.
GRIN2B
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| APIMOSTINEL | ↑ activates | Mechanistic | DGIdb | |
| L701324 | ↓ inhibits | Mechanistic | DGIdb | |
| FELBAMATE | ↓ inhibits | Mechanistic | DGIdb | |
| METHYLPHENIDATE | ? unclear | Mechanistic | DGIdb | |
| CLOZAPINE | ? unclear | Mechanistic | DGIdb | |
| NVP-AAM077 | ↓ inhibits | Mechanistic | DGIdb | |
| GLYCINE | ↑ activates | Mechanistic | DGIdb | |
| SELFOTEL | ↓ inhibits | Mechanistic | DGIdb | |
| AMANTADINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| QUETIAPINE FUMARATE | ? unclear | Mechanistic | DGIdb | |
| L689560 | ↓ inhibits | Mechanistic | DGIdb | |
| LATREPIRDINE | ? unclear | Mechanistic | DGIdb | |
| MG2+ | ↓ inhibits | Mechanistic | DGIdb | |
| TRAXOPRODIL | ↓ inhibits | Mechanistic | 74.0 nM (IC50) | DGIdb |
| VALPROIC ACID | ? unclear | Mechanistic | DGIdb | |
| [3H]DIZOCILPINE | ↓ inhibits | Mechanistic | DGIdb | |
| CNS-5161 | ? unclear | Mechanistic | DGIdb | |
| NEBOGLAMINE | ~ modulates | Mechanistic | DGIdb | |
| NP-10679 | ? unclear | Mechanistic | DGIdb | |
| 5,7-DICHLOROKYNURENIC ACID | ↓ inhibits | Mechanistic | DGIdb | |
| GV196771A | ↓ inhibits | Mechanistic | DGIdb | |
| DIZOCILPINE | ↓ inhibits | Mechanistic | DGIdb | |
| INDANTADOL | ↓ inhibits | Mechanistic | DGIdb | |
| ESKETAMINE HYDROCHLORIDE | ~ modulates | Mechanistic | DGIdb | |
| SEVOFLURANE | ? unclear | Mechanistic | DGIdb | |
| LANICEMINE | ↓ inhibits | Mechanistic | DGIdb | |
| ASPARTIC ACID | ↑ activates | Mechanistic | DGIdb | |
| UBP141 | ↓ inhibits | Mechanistic | DGIdb | |
| DELUCEMINE | ↓ inhibits | Mechanistic | DGIdb | |
| S-DESCHLOROKETAMINE | ↓ inhibits | Mechanistic | DGIdb | |
| RAPASTINEL | ↑ activates | Mechanistic | DGIdb | |
| [3H]L689560 | ↓ inhibits | Mechanistic | DGIdb | |
| EVT-101 | ? unclear | Mechanistic | DGIdb | |
| [3H]D-ASPARTIC ACID | ↑ activates | Mechanistic | DGIdb | |
| [3H]MDL105519 | ↓ inhibits | Mechanistic | DGIdb | |
| ELIPRODIL | ? unclear | Mechanistic | 13.0 nM (Ki) | DGIdb |
| D-CCPENE | ↓ inhibits | Mechanistic | DGIdb | |
| N1-DANSYL-SPERMINE | ↓ inhibits | Mechanistic | DGIdb | |
| ESKETAMINE | ~ modulates | Mechanistic | DGIdb | |
| KETAMINE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb |
Showing top 40 of 236 agents ranked by evidence tier.
GRM5
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| [3H]M-MPEP | ↓ inhibits | Mechanistic | DGIdb | |
| RASEGLURANT | ~ modulates | Mechanistic | DGIdb | |
| GRN-529 | ~ modulates | Mechanistic | DGIdb | |
| GLUTAMIC ACID | ↑ activates | Mechanistic | 11400.0 nM (Ki) | DGIdb |
| FENOBAM ANHYDROUS | ~ modulates | Mechanistic | DGIdb | |
| COMPOUND 41 [PMID: 23434029] | ~ modulates | Mechanistic | DGIdb | |
| DIPRAGLURANT | ~ modulates | Mechanistic | DGIdb | |
| LSN2463359 | ~ modulates | Mechanistic | DGIdb | |
| MAVOGLURANT | ↓ inhibits | Mechanistic | DGIdb | |
| COMPOUND 16M [PMID: 19931453] | ~ modulates | Mechanistic | DGIdb | |
| CDPPB | ~ modulates | Mechanistic | DGIdb | |
| COMPOUND 13 [PMID: 15686941] | ~ modulates | Mechanistic | DGIdb | |
| MPEP | ~ modulates | Mechanistic | DGIdb | |
| AZD6538 | ~ modulates | Mechanistic | DGIdb | |
| COMPOUND 53 [PMID: 23434029] | ~ modulates | Mechanistic | DGIdb | |
| GANCICLOVIR | ? unclear | Mechanistic | DGIdb | |
| STX107 | ~ modulates | Mechanistic | DGIdb | |
| CPPZ | ~ modulates | Mechanistic | DGIdb | |
| CTEP | ~ modulates | Mechanistic | DGIdb | |
| COMPOUND 47 [PMID: 21295468] | ~ modulates | Mechanistic | DGIdb | |
| BOMA | ~ modulates | Mechanistic | DGIdb | |
| COMPOUND 24D [PMID: 23357634] | ~ modulates | Mechanistic | DGIdb | |
| COMPOUND 10 [PMID: 15482906] | ~ modulates | Mechanistic | DGIdb | |
| CHPG | ↑ activates | Mechanistic | DGIdb | |
| COMPOUND 11A [PMID: 14697765] | ~ modulates | Mechanistic | DGIdb | |
| AZD2066 | ~ modulates | Mechanistic | DGIdb | |
| ADX-47273 | ~ modulates | Mechanistic | DGIdb | |
| SIB-1757 | ~ modulates | Mechanistic | DGIdb | |
| MTEB | ~ modulates | Mechanistic | DGIdb | |
| DEHYDRATED ALCOHOL | ? unclear | Mechanistic | DGIdb | |
| COMPOUND 30 [PMID: 21757343] | ~ modulates | Mechanistic | DGIdb | |
| DASOLAMPANEL ETIBUTIL | ↓ inhibits | Mechanistic | DGIdb | |
| AZD2516 | ~ modulates | Mechanistic | DGIdb | |
| COMPOUND 10 [PMID: 15482908] | ~ modulates | Mechanistic | DGIdb | |
| CPPHA | ~ modulates | Mechanistic | DGIdb | |
| 3,3'-DIFLUOROBENZALDAZINE | ~ modulates | Mechanistic | DGIdb | |
| COMPOUND 18 [PMID: 21927650] | ~ modulates | Mechanistic | DGIdb | |
| PTEB | ~ modulates | Mechanistic | DGIdb | |
| VU0409551 | ~ modulates | Mechanistic | DGIdb | |
| COMPOUND 8 [PMID: 15482908] | ~ modulates | Mechanistic | DGIdb |
Showing top 40 of 233 agents ranked by evidence tier.
OPRM1
| Therapeutic Agent | Effect Direction | Evidence Tier | Potency | Source |
|---|---|---|---|---|
| AXOMADOL | ↑ activates | Mechanistic | DGIdb | |
| BMS-986121 | ~ modulates | Mechanistic | DGIdb | |
| DEXTROAMPHETAMINE SULFATE | ? unclear | Mechanistic | DGIdb | |
| METHADONE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| HYDROCODONE POLISTIREX | ↑ activates | Mechanistic | DGIdb | |
| CHEMBL:CHEMBL570176 | ? unclear | Mechanistic | DGIdb | |
| OXYCODONE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| BEVENOPRAN | ↓ inhibits | Mechanistic | DGIdb | |
| EG-1-230 | ↑ activates | Mechanistic | DGIdb | |
| TAPENTADOL | ↑ activates | Mechanistic | DGIdb | |
| BUTORPHANOL | ↑ activates | Mechanistic | DGIdb | |
| CTOP | ↓ inhibits | Mechanistic | DGIdb | |
| NAVACAPRANT | ↓ inhibits | Mechanistic | DGIdb | |
| NALOXONE HYDROCHLORIDE | ↓ inhibits | Mechanistic | DGIdb | |
| CODEINE POLISTIREX | ↑ activates | Mechanistic | DGIdb | |
| LOPERAMIDE | ↑ activates | Mechanistic | DGIdb | |
| ANILERIDINE | ? unclear | Mechanistic | DGIdb | |
| LOFENTANIL | ↑ activates | Mechanistic | DGIdb | |
| LEVOMETHADYL ACETATE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| DEZOCINE | ↑ activates | Mechanistic | DGIdb | |
| FENTANYL HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| QUADAZOCINE | ↓ inhibits | Mechanistic | DGIdb | |
| OXYMORPHONE | ? unclear | Mechanistic | DGIdb | |
| NALDEMEDINE TOSYLATE | ↓ inhibits | Mechanistic | DGIdb | |
| ALFENTANIL HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| ANTICONVULSANT AGENT | ? unclear | Mechanistic | DGIdb | |
| FENTANYL CITRATE | ↑ activates | Mechanistic | DGIdb | |
| NALTREXONE | ↓ inhibits | Mechanistic | DGIdb | |
| NALMEFENE | ↓ inhibits | Mechanistic | DGIdb | |
| REMIFENTANIL HYDROCHLORIDE | ? unclear | Mechanistic | DGIdb | |
| OXYCODONE | ↑ activates | Mechanistic | DGIdb | |
| NALTRIBEN | ↓ inhibits | Mechanistic | DGIdb | |
| PAREGORIC | ↑ activates | Mechanistic | DGIdb | |
| OXYMORPHONE HYDROCHLORIDE | ↑ activates | Mechanistic | DGIdb | |
| ATOXIFENT | ↑ activates | Mechanistic | DGIdb | |
| DYNORPHIN A | ↑ activates | Mechanistic | DGIdb | |
| ERGOT ALKALOIDS | ? unclear | Mechanistic | DGIdb | |
| ALVIMOPAN ANHYDROUS | ↓ inhibits | Mechanistic | DGIdb | |
| METHYLSAMIDORPHAN | ↓ inhibits | Mechanistic | DGIdb | |
| DYNORPHIN A-(1-13) | ↑ activates | Mechanistic | DGIdb |
Showing top 40 of 377 agents ranked by evidence tier.
Clinical Trials
Drug, biologic and supplement trials (treatment or prevention) from ClinicalTrials.gov whose main condition is Alcohol Use Disorder: recruiting, active or completed, most recently updated first. Data retrieved 2026-10-28.
This study is to determine if suvorexant (SUV) will reduce insomnia in 76 men and women veteran and non-veterans between the ages 21-65 with posttraumatic stress disorder (PTSD) symptoms and alcohol use disorder (AUD). All participants will have a 7-day placebo run-in period, followed by a random as...
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with Alcohol Use Disorder (AUD) and hazardous alcohol use. Participation in this study will last approximately 56 weeks.
The purpose of this study is to see if brenipatide when compared to a placebo works and is safe for participants with moderate-to-severe Alcohol Use Disorder (AUD). Participation in this study will last approximately 56 weeks.
Lysergic acid diethylamide (LSD) was investigated in numerous clinical trials during the 1950s and 1960s. Specifically, the use of LSD in the treatment of AUD was investigated extensively. A pooled analysis of six historical clinical trials demonstrated that a single dose of LSD significantly reduce...
Cannabidiol (CBD), one of the most prevalent cannabinoids in cannabis (marijuana) has been shown to reduce alcohol withdrawal symptoms in laboratory animals. In people without alcohol use disorder (AUD), CBD has been show to be effective in reducing anxiety, sleep problems, and seizures; all of thes...
This is a double-blind, placebo-controlled, proof of concept laboratory study to recruit N=70 (35 Males / 35 Females) non-treatment seeking, heavy drinkers with alcohol use disorder (AUD). It is hypothesized that randomization to 1.5mgs dexamethasone versus placebo will decrease alcohol craving duri...
The goal of this research is to replicate findings previously conducted in a pilot trial and to understand, mechanistically, the role of stress in the development of AUD pharmacotherapies that target noradrenergic blockade.
The goal of this clinical trial is to learn if, how, and for whom suvorexant (SUV) works to treat alcohol use disorder (AUD). The main questions it aims to answer are: * Is SUV effective for AUD? * Does SUV dampen stress reactivity? * Can the researchers develop a biomarker for SUV treatment respons...
This clinical trial aims to test the effectiveness and safety of semaglutide, a GLP-1 receptor agonist, in treating moderate to severe alcohol use disorder (AUD) in Veterans. Participants who qualify will be randomly assigned to receive either semaglutide injections or placebo injections over a 24-w...
This human laboratory study aims to assess the effects of cannabidiol on alcohol consumption and craving in participants with alcohol use disorder. In this double-blind within-subject placebo-controlled crossover trial, participants will be randomized to receive both cannabidiol and placebo with a 2...
The goal of this study is to learn how CBD affects drinking in people who drink alcohol regularly. Researchers want to see if CBD can help people drink less and reduce problems related to alcohol use.
The goal of this study is to learn if PT150 can reduce the behavioral and physical effects of stress, alcohol, and alcohol use in people with alcohol use disorder.
Oral disulfiram (Antabuse®) has been shown to improve image-forming vision in animal models with retinal degeneration due to its ability to decrease Retinoic Acid synthesis and consequently reduce hyperactivity in the inner retina. The investigator will aim to evaluate the impact of oral disulfiram ...
Alcohol Use Disorder (AUD) is a common condition that can affect physical and mental health. Current treatments do not work for everyone, and new approaches are needed. The primary aim of this study is to assess whether taking a specific probiotic supplement (a type of "good bacteria") is a feasible...
The study investigators are conducting the first open label pilot trial of MDMA-assisted therapy (MDMA-AT) with a comorbid sample of military veterans with a comorbid diagnosis of Alcohol Use Disorder (AUD) and Post-Traumatic Stress Disorder (PTSD). This novel experimental treatment package consists...
Agents Found By Disease-Level Search
Searched directly from “Alcohol Use Disorder” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 7-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).
40 agents shown (approved or with trial evidence) — 37 not found by the gene-target search above.
AlcoholNOT in gene-target list
N-acetylcysteineNOT in gene-target list
Brief interventionNOT in gene-target list
Treatment as UsualNOT in gene-target list
SuvorexantNOT in gene-target list
Standard therapy for AUDNOT in gene-target list
Standard therapy for TUDNOT in gene-target list
PromillekollNOT in gene-target list
PartyPlannerNOT in gene-target list
TeleCoachNOT in gene-target list
LacosamideNOT in gene-target list
Prize Contingency Management for Alcohol AbstinenceNOT in gene-target list
Standard CareNOT in gene-target list
OnTrackNOT in gene-target list
W-SUDsNOT in gene-target list
ZonisamideNOT in gene-target list
Acamprosate
Naltrexone 380 MGNOT in gene-target list
Ketamine Hydrochloride
Enhanced linkageNOT in gene-target list
ITCNOT in gene-target list
Naltrexone
Cannabis (High% THC) (Inhaled)NOT in gene-target list
Cannabis (Very High% THC) (Inhaled)NOT in gene-target list
Alcohol (oral)NOT in gene-target list
NTX-2001NOT in gene-target list
CBT + EFTNOT in gene-target list
CBT + EFT + CMNOT in gene-target list
Varenicline Tartrate 1 mg b.i.dNOT in gene-target list
Bupropion Hydrochloride 150 mg b.i.dNOT in gene-target list
PioglitazoneNOT in gene-target list
IvermectinNOT in gene-target list
RopivacaineNOT in gene-target list
brief, voluntary substance use interventionNOT in gene-target list
Instranasal OxytocinNOT in gene-target list
Dual ProcessingNOT in gene-target list
Relapse PreventionNOT in gene-target list
Brief Family-Involved Treatment for Alcohol Use DisorderNOT in gene-target list
OxytocinNOT in gene-target list
E-cig useNOT in gene-target list
Generated by the Open Source Medicine Foundation Biomarker Pipeline — 2026-10-08. Data sources: DGIdb, Open Targets, ChEMBL, PubMed, ClinicalTrials.gov. Not medical advice.